Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2025ToxinsOpen Access

Translational Impact of Genetics and Epigenetics of CGRP System on Chronic Migraine Treatment with Onabotulinumtoxin A and Other Biotech Drugs

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDamiana ScuteriPMPaolo Martelletti

Discussion

Loading...

Member takes

Overview

This research examines genetic and epigenetic factors influencing chronic migraine treatment outcomes, suggesting potential pathways for enhanced therapies.

Key Points

  • Onabotulinumtoxin A is used for chronic migraine profylaxis, affecting neurotransmitter release in sensory neurons.
  • Genetic variants related to vascular regulation may influence migraine susceptibility and treatment responses.
  • Epigenetics is an emerging area of study, with limited research on its role in chronic migraine mechanisms.
  • Understanding CGRP's genetic and epigenetic influences could lead to improved treatment options for chronic migraine.

Cite This Study

Scuteri et al. (2025) studied this question.

synapsesocial.com/papers/689a0933e6551bb0af8ce504https://doi.org/10.3390/toxins17070355
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advances in CGRP therapeutic targets for migraine: where do we stand 5 years later?2026 · 1 citations
  2. 2Pharmacology and Pharmacogenomics of Anti-Migraine Drugs2026
  3. 3Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population2024 · 12 citations
  4. 4CGRP and Migraine: Real World Insights and Future Therapeutic Directions2025 · 15 citations
  5. 5CGRP and Migraine: Real World Insights and Future Therapeutic Directions2025